Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Screening:~* signed informed consent~* Age ≥18 years~* patients with MDS or AML after conventional chemotherapy or allogeneic HSCT and positive molecular marker such as t(6,9), NPM1 pos. or CD34+ or CD117+ in the case of an allogeneic HSCT~Treatment:~* MDS or AML without haematological relapse (blasts \<5% in the bone marrow), and~* decrease of CD34 donor chimerism (\<80%) after allogeneic related or unrelated HSCT in CD34+ or CD117+ MDS or AML or~* increase in the AML-specific molecular marker in the quantitative PCR for t(6,9), NPM1+ AML \>1% after conventional chemotherapy or allogeneic HSCT or~* persistence of the (above) MRD levels \>1% (relative to the reference gene) after conventional chemotherapy or allogeneic HSCT~* leukocytes \> 3 Gpt/l and platelets \>75 Gpt/l (transfusion independent)~Exclusion Criteria:~* Known history of hypersensitivity to any of the drugs used or their constituents or to drugs with similar chemical structure,~* Participation of the patient in another clinical trial within the last 4 weeks before the inclusion~* addiction or other disorders that do not allow the concerned person, to assess the nature and scope and possible consequences in the clinical investigation~* pregnant or breast feeding women~* women of childbearing potential, except women who meet the following criteria:~  * post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum FSH \>40 U/ml)~ * postoperative (6 weeks after hysterectomy with or without bilateral ovariectomy )~ * regular and proper use of a contraceptive method with error rate \<1% per year (e.g., implants, depot injections, oral contraceptives, intrauterine device, IUD) during study treatment and up to 1 year after completion of therapy~ * sexual abstinence during study treatment and up to 1 year after completion of therapy~ * Vasectomy of the partner~* Men who do not use one of the following types of effective contraception during study treatment and up to 1 year after completion of therapy:~  * sexual abstinence~ * State post-vasectomy~ * Condom~* Evidence that the participating person is not expected to comply with the protocol (such as lack of cooperation)~* Uncontrolled active infection~* Severe hepatic impairment (AST and ALT may not exceed three times the normal) or liver cirrhosis or malignant liver tumor~* Dialysis dependent renal dysfunction~* Known severe congestive heart failure, incidence of clinically unstable cardiac or pulmonary disease These criteria are not for the screening phase up to a known allergic reaction to azacitidine or intolerance to apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacytidine (Type: EXPERIMENTAL): Azacytidine injection: 75 mg/m²/d, subcutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).